Peter Chambré
Administration
Immatics Biotechnologies
Germany
Biography
Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies. He was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company. Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012 Non-executive Director of BTG plc. He joined Immatics as Chairman of the Board in November 2012.
Research Interest
Pharmaceutical Science
